Answers are grounded in this paper and cite their sources.
BACKGROUND: Many older patients with acute myeloid leukemia (AML) are ineligible for intensive chemotherapy. Quizartinib, an oral, selective, FMS-like tyrosine kinase 3 (FLT3) inhibitor is approved in combination with intensive chemotherapy for patients with newly diagnosed (ND) FLT3-internal tandem duplication (ITD)-positive AML. Quizartinib efficacy and safety in combination with venetoclax plus either azacitidine (VEN-AZA-Quiz) or low-dose cytarabine (VEN-LDAC-Quiz) were investigated in patients ineligible for intensive chemotherapy. METHODS: The phase I/II, multicenter, prospective, open-label, VEN-A-QUI trial enrolled patients aged ≥ 60 years with ND FLT3-ITD-positive or -negative AML. PHASE I: patients were assigned to parallel VEN-AZA-Quiz or VEN-LDAC-Quiz dose-escalation cohorts. PHASE II: patients were randomized 1:1 to VEN-AZA-Quiz or VEN-LDAC-Quiz. Primary endpoints were the determination of quizartinib recommended phase II dose (RP2D; phase I) and composite complete remission (CRc) rate (phase II). RESULTS: Fourteen and 60 patients received treatment in phase I and II, respectively. The quizartinib RP2D was 60 mg/day for VEN-AZA-Quiz and 40 mg/day for VEN-LDAC-Quiz. In phase II, CRc by Cycle 4 was achieved in 18/31 patients (58.1%) receiving VEN-AZA-Quiz and 15/29 (51.7%) receiving VEN-LDAC-Quiz (p = 0.80). Median overall survival (OS) was 16.9 months and 8.9 months for VEN-AZA-Quiz and VEN-LDAC-Quiz, respectively (p = 0.81), with 3-year OS rates of 22.6% and 27.6%. Overall, a high CRc rate (10/13, 76.9%) and median OS (29.3 months) was observed in FLT3-ITD-positive patients. Median OS was 32 months for de novo AML and 7.5 months for secondary AML (p < 0.001). The most common adverse events were infectious and hematologic toxicity. CONCLUSIONS: VEN-AZA-Quiz and VEN-LDAC-Quiz regimens demonstrated clinical activity in patients with ND AML aged ≥ 60 years ineligible for intense chemotherapy, particularly in patients with de novo AML, with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04687761.
No takes yet. Share an insight, caveat, or question.
Bergua et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: